Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in RLAY.

← Back to Free Index

RLAY

Analysis as of: 2026-07-14

Relay Therapeutics, Inc.

Relay Therapeutics is a clinical-stage biotechnology company developing precision small-molecule medicines, led by zovegalisib in breast cancer and vascular anomalies.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Focused Franchise Potential, Concentrated Proof Risk

One asset can plausibly open a real breast cancer business and a second rare-disease leg by 2031. The catch is simple: the equity still lives or dies on pivotal execution and regulatory follow-through.

Analysis

Thesis

Relay is a concentrated but asymmetric biotech: if zovegalisib converts its current safety and efficacy profile into approvals across second-line breast cancer plus vascular anomalies, while keeping a credible frontline path alive, one molecule can create a real franchise and validate the broader discovery engine by 2031.

Last Economy Alignment

Relay benefits from cheaper AI-driven discovery because its value sits in molecule IP and clinical permissioning, not software seats. The bottleneck is still human trials and FDA proof, so it is helped by the Last Economy but does not define it.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.8x (from 5 most recent analyses)

Reasoning

The upside comes from one asset becoming a focused franchise in two real markets while preserving a frontline option. That can support strong compounding and a higher quality revenue mix, but not a 10x case because the company is still pre-commercial, highly concentrated, and already priced for meaningful success.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is mainly a concentrated proof story. The biggest risks are pivotal validation, FDA path clarity, and whether one molecule can really support two commercial franchises before cash burn, dilution, or competitive data narrow the payoff.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No company-issued clinical, regulatory, or financing update appeared in the last 7-10 days; the latest fresh operating disclosures still come from May 2026.
Recent SEC activity was routine insider Form 4 flow rather than program or balance-sheet news.
Near-term positioning still hinges on the next formal update on ReDiscover-2 execution, vascular-anomalies follow-up, and cash runway.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.29

They use AI and protein-motion data to design drugs, but they only get paid if those molecules win in humans and with regulators. That gives them a real edge in discovery, yet the main bottleneck is still trial proof, not software scale.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$24.25

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research